<DOC>
	<DOCNO>NCT02401620</DOCNO>
	<brief_summary>The purpose present study assess measurement property tolerability questionnaire . The result obtain patient Rheumatoid Arthritis ( RA ) treat robust ass patient 's tolerability treatment . Patients great tolerability satisfy treatment .</brief_summary>
	<brief_title>Validation Tolerability Questionnaire Rheumatoid Arthritis</brief_title>
	<detailed_description>Clinicians standardize questionnaire ass tolerability patient 's perspective . The tolerability assessment different pharmacological strategy Rheumatoid Arthritis , patient 's perspective , would provide additional information , improve doctor-patient communication improve adherence efficacy treatment . For reason , development validation new tool necessary future research , use standard clinical practice . The first phase development questionnaire already complete . The second phase development questionnaire design validate tool Spanish population . This study aim assess measurement property new tool ass impact daily life Rheumatoid Arthritis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>1 . Patients 18 year old . 2 . Patients RA diagnose accord standard ACR ( American College Rheumatology ) 1987 ACR/EULAR 2010 3 . Patients treatment Rheumatoid Arthritis drug least 3 month inclusion study * 4 . Patients provide informed consent prior take part study . It 's necessary patient treat firstline moment inclusion study . 1 . Patients rheumatic disease Rheumatoid Arthritis . Will exclude patient follow concomitant disease : Rheumatic autoimmune disease RA ; Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis ; Diagnosis juvenile idiopathic arthritis ; inflammatory joint disease Rheumatoid Arthritis . 2 . Patients concomitant disease treatment , clinical criterion , could affect result study major episode infection disease require hospitalization . 3 . Patients medical physiological condition , view investigator , could compromise ability patient answer study question . 4 . Patients participate interviews Phase I ( development questionnaire )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>AR : arthritis rheumatoid</keyword>
	<keyword>DMARDs : Disease-modifying antirheumatic drug</keyword>
	<keyword>ACR . American College Rheumatology</keyword>
	<keyword>EULAR : European League rheumatology</keyword>
</DOC>